



## Multi-Ethnic Study of Atherosclerosis: Objectives and Design

**Diane E. Bild<sup>1</sup>, David A. Bluemke<sup>2</sup>, Gregory L. Burke<sup>3</sup>, Robert Detrano<sup>4</sup>, Ana V. Diez Roux<sup>5</sup>, Aaron R. Folsom<sup>6</sup>, Philip Greenland<sup>7</sup>, David R. Jacobs, Jr.<sup>6</sup>, Richard Kronmal<sup>8</sup>, Kiang Liu<sup>7</sup>, Jennifer Clark Nelson<sup>8</sup>, Daniel O'Leary<sup>9</sup>, Mohammed F. Saad<sup>10</sup>, Steven Shea<sup>5</sup>, Moyses Szklo<sup>11</sup>, and Russell P. Tracy<sup>12</sup>**

<sup>1</sup> Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, MD.

<sup>2</sup> Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD.

<sup>3</sup> Department of Public Health Sciences, School of Medicine, Wake Forest University, Winston-Salem, NC.

<sup>4</sup> Harbor-UCLA Research and Education Institute, Los Angeles, CA.

<sup>5</sup> Departments of Medicine and Epidemiology, Schools of Medicine and Public Health, Columbia University, New York, NY.

<sup>6</sup> Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, MN.

<sup>7</sup> Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.

<sup>8</sup> Department of Biostatistics, School of Public Health and Community Medicine, University of Washington, Seattle, WA.

<sup>9</sup> Department of Radiology, New England Medical Center, Boston, MA.

<sup>10</sup> Department of Medicine, School of Medicine, University of California, Los Angeles, Los Angeles, CA.

<sup>11</sup> Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.

<sup>12</sup> Laboratory for Clinical Biochemistry Research, Departments of Pathology and Biochemistry, College of Medicine, University of Vermont, Burlington, VT.

*Received for publication October 30, 2001; accepted for publication June 19, 2002.*

The Multi-Ethnic Study of Atherosclerosis was initiated in July 2000 to investigate the prevalence, correlates, and progression of subclinical cardiovascular disease (CVD) in a population-based sample of 6,500 men and women aged 45–84 years. The cohort will be selected from six US field centers. Approximately 38% of the cohort will be White, 28% African-American, 23% Hispanic, and 11% Asian (of Chinese descent). Baseline measurements will include measurement of coronary calcium using computed tomography; measurement of ventricular mass and function using cardiac magnetic resonance imaging; measurement of flow-mediated brachial artery endothelial vasodilation, carotid intimal-medial wall thickness, and distensibility of the carotid arteries using ultrasonography; measurement of peripheral vascular disease using ankle and brachial blood pressures; electrocardiography; and assessments of microalbuminuria, standard CVD risk factors, sociodemographic factors, life habits, and psychosocial factors. Blood samples will be assayed for putative biochemical risk factors and stored for use in nested case-control studies. DNA will be extracted and lymphocytes will be immortalized for genetic studies. Measurement of selected subclinical disease indicators and risk factors will be repeated for the study of progression over 7 years. Participants will be followed through 2008 for identification and characterization of CVD events, including acute myocardial infarction and other coronary heart disease, stroke, peripheral vascular disease, and congestive heart failure; therapeutic interventions for CVD; and mortality.

cardiovascular diseases; cardiovascular system; cohort studies; coronary disease; epidemiologic methods; prospective studies

Abbreviations: CVD, cardiovascular disease; MESA, Multi-Ethnic Study of Atherosclerosis.

Prospective epidemiologic studies of cardiovascular disease (CVD) have traditionally relied on the occurrence of clinically overt events, such as myocardial infarction, stroke,

and coronary heart disease death, to identify factors predicting development of disease. This design has served well to identify many CVD risk factors, but more recent

Correspondence to Dr. Diane E. Bild, MESA Coordinating Center, Building 29, Suite 310, 6200 NE 74th Street, Seattle, WA 98115 (e-mail: bildd@nhlbi.nih.gov).

study designs utilizing earlier, subclinical endpoints hold promise for furthering our capacity to predict and prevent CVD. The Multi-Ethnic Study of Atherosclerosis (MESA) was initiated by the National Heart, Lung, and Blood Institute to further understanding of the pathogenesis of atherosclerosis and other CVD by 1) providing accurate, quantifiable measures of early CVD; 2) characterizing CVD before it has become clinically manifest and therefore subject to interventions that disrupt its natural history; and 3) optimizing study of the progression of subclinical disease. The study will include populations that will provide information about specific ethnic groups and allow comparisons among groups at different levels of risk that may provide clues to pathogenesis. This paper describes the rationale and design of MESA.

There are several advantages to using measures of subclinical disease—that is, disease detected noninvasively before it produces clinical signs and symptoms—in studies of disease etiology. First, although clinical events are the usual targets of clinical and public health intervention, studies based solely on clinical events may lead to distortion of risk relations due to underdetection and biased ascertainment of disease. Second, subclinical disease measures can enhance studies of CVD risk and prevention by allowing examination of its early stages. Third, because subclinical disease is asymptomatic and previously unknown to participants, it is unlikely to have any direct impact on health behaviors, such as lifestyle modification or medication use, that may alter relations of risk with disease. (This applies particularly to cross-sectional analyses; it is expected that knowledge of baseline subclinical disease imparted to study participants often results in interventions that will modify the risk of clinical outcomes longitudinally.) Finally, the continuous nature of most subclinical measures greatly increases power to detect risk associations compared with discrete measures, that is, the presence or absence of clinical disease.

MESA will build upon the successful experience of several CVD epidemiologic studies begun since the 1980s that have included objective measures of subclinical CVD. Examples of these measures are echocardiographically measured left ventricular mass and carotid ultrasonographic measurement of arterial wall thickness, which have been used in the Framingham Study (1), the Cardiovascular Health Study (2), and the Atherosclerosis Risk in Communities Study (3) to detect underlying subclinical disease and predict clinical CVD (4). Recent developments in the measurement of cardiovascular structure and function make imaging of other aspects of subclinical disease and measuring functional aspects of the vasculature in population-based studies feasible and accurate, providing specific, detailed information that relates more directly to pathology. Coronary calcium is a specific marker of atherosclerosis (5) that has been included in the Coronary Artery Risk Development in Young Adults Study (6) and in subgroups in the Atherosclerosis Risk in Communities Study and the Cardiovascular Health Study (7). When quantified by computed tomography, coronary calcium has correlations of 0.90 or greater with histologic coronary plaque area (8, 9), and it can be used to identify persons at increased risk for coronary heart disease events (10, 11), although some studies of the

predictive value of coronary calcium have been criticized for drawing participants from clinical or high-risk populations. Cardiac magnetic resonance imaging, which has not been utilized in previous epidemiologic studies, is capable of providing precise measures of left ventricular mass, diastolic and systolic function, and aortic distensibility (12–14). Magnetic resonance imaging of the carotid wall may provide an opportunity for improved assessment of plaque characteristics (15) and their relation to clinically overt disease in the carotid arterial bed (16). Vascular stiffness, other aspects of arterial mechanics, and endothelial function are additional noninvasive measures of “early” functional changes in the vasculature that are related to existing disease, risk factor exposure, and risk factor alteration (17–20). Some measures of arterial structure and dynamics may be obtained relatively quickly, inexpensively, and noninvasively and thus could have clinical application as screening and monitoring tools or as a means of guiding therapy (21–24). MESA will include all of these measures, with cardiac magnetic resonance imaging providing measures previously obtained by echocardiography and, in a subset, carotid magnetic resonance imaging. The predictive value of these measures will be compared and combined to obtain a thorough evaluation of cardiovascular physiology and pathology.

Findings from studies of risk factors for subclinical CVD have implications for prevention beyond that of clinical CVD (25–27). The risk of clinical events associated with subclinical disease measures has been shown to be graded and continuous (1, 2, 4, 11), similar to risk associated with conventional CVD risk factors such as blood pressure and serum cholesterol, suggesting that interventions yielding even modest reductions in levels of subclinical disease may have a significant impact on reducing CVD risk throughout the general population. For such interventions to be designed, factors contributing to the development and progression of subclinical disease must be identified. Despite the value of understanding subclinical disease in asymptomatic populations, it is clear that there is a qualitative difference between subclinical and clinical disease burden that precludes replacement of the former with the latter. The use of subclinical disease measures is controversial for use in clinical trials as a surrogate outcome measure (28). In MESA, however, subclinical disease is an outcome measure in itself, and it is being used as a window into the early pathogenesis of clinical disease.

Atherosclerosis is a complex process involving inflammation and cellular proliferation in the arterial wall that is mediated by a variety of growth factors, cytokines, thrombotic factors, and vasoactive molecules (29). Mature lesions exhibit calcification (30), which is mediated by cells similar to osteoblasts (31, 32). Infectious agents may be involved in the initiation and/or progression of atherosclerotic lesions (33). Roles have been suggested for a host of other factors in the etiology of atherosclerosis and of clinical events (34), including hemostatic factors (35, 36), factors related to lipoprotein metabolism, insulin resistance (37), homocysteine (29), immune factors (38), inflammation markers (39), specific fatty acids (40, 41), indicators of oxidative stress, and circulating markers of endothelial function such as cellular adhesion molecules and thrombomodulin (42).

Prospective investigation of these potential risk factors should suggest pathophysiologic mechanisms likely to be involved. MESA will systematically evaluate each of these domains in the whole cohort or in informative subgroups.

Advances in techniques for identifying genetic markers and sequencing genes and in statistical methods for analyzing genetic epidemiologic data have opened opportunities for estimating gene frequencies in populations, exploring the relations between genes and phenotypes, and understanding gene-gene and gene-environment interactions (43). Characterization of subclinical disease in MESA should result in more precise and valid phenotypic characterization of CVD than in past studies, enhancing the ability to relate specific blood markers and specific genes or chromosomal regions to phenotypes.

The incidence and prevalence of CVD differ among some racial and ethnic groups in the United States. Information on subclinical CVD in some groups is sparse, however. MESA will include a substantial proportion of previously understudied minority groups whose prevalence of risk factors and CVD risk attributable to specific risk factors have been shown or hypothesized to differ from that of the majority of the population. African Americans tend to have higher CVD rates than do Whites, particularly among women (44, 45). Hispanic populations in the United States, notwithstanding their ethnic and cultural heterogeneity, tend to have lower rates of CVD and general mortality than the general population does, despite high risk factor levels, although data are not consistent in this regard (46–48). Pacific Asians (particularly Chinese Americans, Japanese Americans, and immigrants from Southeast Asia) have lower morbidity and mortality rates than do Whites (49, 50). However, there are few data available on this group, particularly Pacific-Asian women in the United States. By including several ethnic groups, MESA will provide information on the progression of subclinical CVD in these groups, including whether risk factor-outcome relations differ across groups. In recognition of the need to obtain more health information on ethnic minority groups, in recent years policies governing funding of clinical research by the National Institutes of Health have mandated the inclusion of minorities (51). MESA will contribute importantly to accumulating data on CVD and its risk factors in minority groups.

## MATERIALS AND METHODS

### Study objectives

The objectives of MESA are 1) to determine characteristics related to progression of subclinical CVD to clinical CVD; 2) to determine characteristics related to progression of subclinical CVD itself; 3) to assess ethnic, age, and sex differences in subclinical disease prevalence, risk of progression, and rates of clinical CVD; 4) to determine relations of newly identified factors with subclinical disease and to determine their incremental predictive value over established risk factors; and 5) to develop methods, suitable for application in future screening and intervention studies, for characterizing risk among asymptomatic persons.

### Study design

Study participants will include 6,500 men and women, in equal numbers, who are aged 45–84 years and free of clinical CVD at baseline, including four racial/ethnic groups from six US communities. Approximately 38 percent of the cohort will be White, 28 percent will be African-American, 23 percent will be Hispanic, and 11 percent will be Asian, predominantly of Chinese descent. The first examination, which began in July 2000 and will be conducted over a 24-month period, is designed to be the most comprehensive. The second (from July 2002 to January 2004) and third (from January 2004 to July 2005) examinations, conducted over 18 months each, will include repetitions of selected baseline measurements and new measures that could not be included at baseline. The fourth examination (from July 2005 to July 2007), to be conducted over a 24-month period, will include repetition of selected measures to be studied for temporal trends. The MESA protocol, including information about the source populations from which recruitment occurred, detailed exclusion criteria, contact information for the investigators, and other information, is available on the World Wide Web at [www.mesa-nhlbi.org](http://www.mesa-nhlbi.org).

*Subclinical CVD prevalence and progression and CVD events.* With coronary artery calcium as an indicator, the prevalence of subclinical disease is expected to range from approximately one fourth in the youngest women to virtually 100 percent in the oldest participants (52). Dramatic differences in the prevalence of coronary calcium with age and the findings of longitudinal studies (53, 54) suggest that progression is easily observable and measurable.

With the baseline cross-sectional data, for an alpha error of 5 percent, the study will have more than 95 percent power to identify relations between risk factors with a prevalence of at least 10 percent in the cohort and the presence of coronary calcium, with an odds ratio of 1.5 or greater (table 1, top). The power to test similar hypotheses in women and Hispanics will be 81 percent and 59 percent, respectively. Analytical methods that utilize the continuous nature of coronary calcium will significantly enhance power.

It is expected that there will be approximately 330 coronary heart disease events, defined as coronary heart disease death or nonfatal myocardial infarction, over the first 6 years of follow-up (table 2). The rates shown in table 2 are based on observed events in the Atherosclerosis Risk in Communities Study and the Cardiovascular Health Study for Whites and Blacks (unpublished data), with the assumption that event rates in Hispanic subgroups would be 80 percent of those in the White subgroup (46) and that event rates in the Asian subgroup would be 60 percent of those in the White subgroup (55). To take into account possible interventions that could result from participants' and their physicians' discovering subclinical CVD, we decreased the estimated event rate in one fifth of the cohort (those with the highest coronary calcium scores) by one third. With these assumptions, the power to detect a relative risk of 2.0 associated with the presence of a risk factor in 10 percent of the population would be more than 95 percent in the entire cohort, 70 percent in women, and less than 50 percent in Hispanics (table 1, bottom). A complete table on the study's statistical

**TABLE 1. Statistical power to test hypotheses related to coronary artery calcium level in the Multi-Ethnic Study of Atherosclerosis\***

*Cross-sectional analyses: prevalence of a cardiovascular disease risk factor related to the prevalence of coronary calcification in the MESA† cohort and in subgroups of women and Hispanics*

Prevalence (%) of risk factor in controls	Odds ratio	Statistical power (%)		
		Entire cohort (n = 6,500) (prevalence of coronary calcium at baseline = 40%)	Women (n = 3,250) (prevalence of coronary calcium at baseline = 20%)	Hispanics (n = 1,495) (prevalence of coronary calcium at baseline = 40%)
10	1.5	>95	81	59
	2.0	>95	>95	>95
30	1.5	>95	>95	91
	2.0	>95	>95	>95

*Development of clinical events: prediction of events from a cardiovascular disease risk factor over a period of 5 years*

Prevalence of risk factor (%)	Relative risk	Statistical power (%)		
		Entire cohort	Women	Hispanics
10	1.5	63	<50	<50
	2.0	>95	70	<50
30	1.5	91	~50	<50
	2.0	>95	92	72

\* Power estimates are based on an EGRET sample size program, logistic regression for a cohort study design, adjustment for age and sex (estimates for women are adjusted for age only), analytical estimation methods (84), and an alpha level of 0.05.

† MESA, Multi-Ethnic Study of Atherosclerosis.

power to test these hypotheses in different subgroups is available in the Web-based protocol at [www.mesa-nhlbi.org](http://www.mesa-nhlbi.org).

**Study communities.** The MESA cohort is being drawn from six regions in the United States: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth

**TABLE 2. Expected rates of coronary heart disease death and nonfatal myocardial infarction in the Multi-Ethnic Study of Atherosclerosis over a period of 6 years\***

	Event rate (%)	No. of events
All participants	5.1	330
Sex		
Men	6.7	217
Women	3.5	114
Race/ethnicity		
Whites	4.9	122
Blacks	6.7	121
Hispanics	4.3	65
Asians	3.2	23

\* Assumes that there are 6,500 participants aged 45–84 years who were free of coronary heart disease at baseline. Other assumptions are given in the text. Event rates are based on those observed in the Atherosclerosis Risk in Communities Study (1987–1994) and the Cardiovascular Health Study (1989–1997) (unpublished data).

County, North Carolina; Los Angeles County, California; New York, New York; and St. Paul, Minnesota. At each site, approximately 1,083 eligible participants will be recruited, with equal numbers of men and women, according to specified age/race/ethnicity proportions. Information about the source populations from which the cohort is being recruited may be found in the Web-based protocol.

**Recruitment.** Each of the six field centers will recruit an equal number of men and women from two or more of the racial/ethnic groups. The expected marginal distributions of race/ethnicity, overall and at each field center, are shown in table 3. In designing center-specific recruitment goals, it was deemed important to have overlapping ethnic groups among field centers to minimize confounding of ethnicity by site.

Except when random digit dialing is used, an informational brochure is being mailed to households in targeted areas. Within 14 days, households are contacted by telephone; the language spoken in the home is determined; and a questionnaire is administered in English, Spanish, Cantonese, or Mandarin to introduce the study and collect eligibility information. All eligible persons are enumerated. To augment recruitment of elderly members of minority groups, toward the end of the recruitment period, participants were asked to refer elderly persons to the study. A complete list of the exclusion criteria is available in the Web-based protocol. Other than exclusions made because of a lack of age or race/ethnicity eligibility, exclusions will be made to eliminate prevalent CVD or for reasons of safety or

**TABLE 3. Ethnic distribution goals for participants in the Multi-Ethnic Study of Atherosclerosis, overall and by field center**

	Whites		African Americans		Hispanics		Asian Americans		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%
Forsyth County, North Carolina	542	50	542	50					1,083	100
St. Paul, Minnesota	542	50			542	50			1,083	100
Chicago, Illinois	542	50	271	25			271	25	1,083	100
New York, New York	217	20	379	35	488	45			1,083	100
Baltimore, Maryland	542	50	542	50					1,083	100
Los Angeles County, California	108	10	108	10	433	40	433	40	1,083	100
Overall	2,492	38	1,842	28	1,463	23	704	11	6,500	100

feasibility. Those with prevalent CVD will be excluded to optimize the study of subclinical CVD progression and predictors of clinical CVD.

### Examination components

Informed consent is obtained from participants upon their arrival at the study clinic. Table 4 provides a list of the planned components by examination. Specific variables on

which data will be obtained as measures of subclinical disease are listed in the Appendix. The institutional review boards of the six field centers have approved the study protocol.

The components of the first examination are as follows. Information is gathered on questionnaires to ascertain each participant's contacts, demographic data, Social Security number (to facilitate tracking and linking with the National Death Index), tobacco usage, passive smoke exposure,

**TABLE 4. Components of the Multi-Ethnic Study of Atherosclerosis, by examination\***

Component	Examination 1 (July 2000– July 2002)	Examination 2 (July 2002– January 2004)	Examination 3 (January 2004– July 2005)	Examination 4 (July 2005– July 2007)
Medical history	X	X	X	X
Personal history, demographic data, and socioeconomic status	X	X	X	X
Medications	X	X	X	X
Psychosocial assessment	X	X	X	X
Diet assessment	X			
Physical activity	X	X	X	X
Family history		X		
Anthropometry	X	X	X	X
Blood pressure	X	X	X	X
Electrocardiography	X			X
Spot urine collection for microalbuminuria	X			
Phlebotomy	X	X	X	X
Carotid ultrasound	X			
Ankle brachial index	X		X	
Endothelial function	X			
Arterial wave form collection	X			
Cardiac CT† scanning	X	50%	50%	25%
Cardiac MRI† scanning	X			25%
Carotid MRI scanning		(n = 600)		

\* Examination components and proportions or numbers in subsets, particularly for examinations 2, 3, and 4, are subject to change.

† CT, computed tomography; MRI, magnetic resonance imaging.

alcohol consumption, medical conditions, access to medical care, family history of CVD, reproductive history (in women), and current use of prescription and nonprescription medications and supplements (56). Physical activity is measured by using a detailed, semiquantitative questionnaire adapted from the Cross-Cultural Activity Participation Study (B. Ainsworth, University of South Carolina, personal communication, 2000). Usual diet during the previous year is characterized by means of a food frequency questionnaire modified from the Insulin Resistance Atherosclerosis Study instrument, in which comparable validity was observed for non-Hispanic White, African-American, and Hispanic persons (57, 58), and modified to include foods typically eaten by Chinese persons and to collect supplemental information concerning hypotheses about whole grains, processing of plant food, and flavonoids. Questionnaires are administered at baseline to capture information about anger and anxiety (the Spielberger trait anger and anxiety scales) (59), depression (the Center for Epidemiologic Studies Depression Scale (60)), social support (61), chronic psychological stress (the chronic burden scale developed for the Healthy Women Study (62)), perception of discrimination and unfair treatment (63, 64), and neighborhood environment, including measures of social cohesion (65) and selected aspects of the physical environment. Additional psychosocial domains to be assessed in follow-up visits include optimism (the Life Orientation Test (66)), hostility (a subset of the Cook-Medley scale (67)), religiousness/spirituality (68), job stress (69), and quality of life (70).

During the examination, height, weight, and waist and hip circumferences are measured. Resting blood pressure is measured three times in the seated position using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, Tampa, Florida) (71). The average of the last two measurements will be used in analysis.

Chest computed tomography is performed using either a cardiac-gated electron-beam computed tomography scanner (the Chicago, Los Angeles, and New York field centers) (Imatron C-150; Imatron, San Francisco, California) (72) or a prospectively electrocardiogram-triggered scan acquisition at 50 percent of the R-R interval with a multidetector computed tomography system (73) acquiring a block of four 2.5-mm slices for each cardiac cycle in a sequential or axial scan mode (the Baltimore, Forsyth County, and St. Paul field centers) (Lightspeed, General Electric Medical Systems, Waukesha, Wisconsin; or Volume Zoom, Siemens, Erlanger, Germany). All participants are scanned over phantoms of known physical calcium concentration. Scans are read centrally at the Harbor-UCLA Research and Education Institute in Torrance, California, to identify and quantify coronary calcification, calibrated according to the readings of the calcium phantom.

Cardiac magnetic resonance imaging is performed using scanners with 1.5-T magnets. The following models are being used: Forsyth County—Signa CV/i (General Electric Medical Systems, Waukesha, Wisconsin); New York—Signa LX (General Electric); Baltimore—Signa CV/i (General Electric); St. Paul—Vision and Symphony (Siemens, Erlanger, Germany); Chicago—Symphony (Siemens); Los Angeles—Vision (Siemens) and Signa LX

(General Electric). All imaging is performed with a four-element, phased-array surface coil placed anteriorly and posteriorly, electrocardiogram gating, and brachial artery pressure blood pressure monitoring. Imaging consists of cine images of the left ventricle with time resolution less than 50 msec, as well as phase contrast flow images of the ascending aorta (74, 75). Images of the carotid arteries (planned for the second examination) will be obtained with dedicated surface coils for plaque characterization (76). Readings will be performed centrally at the Department of Radiology, Johns Hopkins University School of Medicine.

For carotid ultrasonography, images of the right and left common carotid and internal carotid arteries are captured, including images of the near and far wall, using high-resolution B-mode ultrasound (77). Doppler studies of the common carotid artery, the internal carotid artery, and the bulb and distensibility of the distal common carotid artery are obtained (78, 79). The Logiq 700 ultrasound machine (General Electric Medical Systems) is used at all centers. Readings are performed centrally at the Department of Radiology, New England Medical Center.

High-resolution B-mode ultrasound imaging is used to determine the diameter of the right brachial artery before and immediately after reactive dilation induced by ischemia (80), which is produced by inflating a blood pressure cuff to 200 mmHg or to 50 mmHg greater than the systolic blood pressure (whichever is higher) for 5 minutes. Arterial diameter at baseline and at 60 seconds after cuff deflation are recorded; the percentage difference is the measure of reactivity. Readings are performed centrally at the Department of Radiology, New England Medical Center.

Arterial wave forms are recorded using the HDI/Pulse-Wave CR2000 (Hypertension Diagnostics, Inc., Minneapolis, Minnesota) (81). With a tonometer at the radial artery, 10 arterial wave forms will be collected and stored electronically. On the basis of these measures, plus the participant's age, sex, height, and weight, measures of small and large artery compliance are produced by the device using the manufacturer's software. Additional readings are performed centrally at the Department of Radiology, New England Medical Center.

To obtain the ankle-brachial blood pressure index, blood pressure is measured with a Doppler probe in the bilateral brachial, dorsalis pedis, and posterior tibial arteries (82). The higher of the pressures obtained in the same ankle will be used as the numerator for the ankle-brachial blood pressure index for that leg.

For electrocardiography, three 12-lead recordings are obtained using a Marquette MAC-PC instrument (Marquette Electronics, Milwaukee, Wisconsin) and read using Nova-code criteria (83). In addition to standard electrocardiogram-derived measures, information on R-R variability is obtained. Readings are performed centrally at Wake Forest University.

Blood is drawn from participants, and aliquots are prepared for central analysis and for storage (approximately 65 aliquots per participant) at the University of Vermont and the University of Minnesota. Measurements will be performed to allow several domains of study to be addressed, including lipids and lipoproteins, systemic inflammation,

hemostasis and fibrinolysis, insulin resistance, oxidative damage and stress, plaque destabilization, endothelial cell function, bone metabolism, endocrinology, and nutrition. DNA is extracted from the buffy coat, and white blood cells are prepared for cryopreservation and later immortalization of the lymphocytes. Red blood cell membranes are prepared and stored for subsequent analysis. A random urine sample is collected, with one aliquot being analyzed centrally for albumin and creatinine and the remainder stored.

### Notification of and referral for study findings

Study participants and their physicians, as requested by the participant, receive information on relevant medical tests. An initial report summarizes results available at the completion of the first clinic visit, such as height, weight, blood pressure, and preliminary electrocardiographic findings. Routine laboratory findings of clinical relevance and results of computed tomography, magnetic resonance imaging, and ultrasonography are reported by mail. Any "alert" findings—indications of conditions that should be medically evaluated on an urgent basis—are reported to the participant and his or her physician by telephone as soon as they are identified.

### Cohort surveillance and follow-up for events

Study event endpoints will include acute myocardial infarction and other forms of coronary heart disease, stroke, peripheral vascular disease, and congestive heart failure; mortality; and CVD interventions. Silent myocardial infarctions will be identified using criteria applied to the follow-up electrocardiogram. Resuscitated cardiac arrest and other CVD endpoints, such as procedure-induced events or pulmonary embolism, will be identified from medical records. Each participant will be contacted every 9–12 months. Information on new CVD conditions, hospitalizations, treatments, and changes in life habits recently instituted will be obtained. At the first follow-up contact, emphasis will be placed on obtaining information on diagnostic assessment or treatment that might have been related to the report of subclinical disease measured at baseline.

For classification of CVD events occurring during follow-up in MESA, information will be collected from death certificates, medical records from hospitalizations, autopsy reports, interviews with participants, and, in the case of out-of-hospital deaths, interviews with or questionnaires administered to physicians, relatives, or friends.

### Quality assurance and control

Staff are centrally trained and are required to demonstrate competency in relevant procedures before being certified to perform those procedures for the MESA examination. This includes all interviews, phlebotomy and specimen processing, all blood pressure measurements, anthropometry, electrocardiography, ultrasound procedures, collection of arterial wave forms, computed tomography, magnetic resonance imaging, and data entry. Certification is main-

tained by successful performance of the procedure over time, which is monitored by the MESA Coordinating Center.

Duplicate collections and/or measurements for a subsample of components, except interviews, will be obtained to measure reproducibility. The validity of all measurements will be checked through examination of data outliers and through external quality control programs (for example, routine measurement of scans obtained from phantoms and performance in independent laboratory quality maintenance programs).

### Data management

Data collected at the field centers are entered onto forms that are scanned and transmitted to the MESA Coordinating Center. The scanning software confirms the validity of identification numbers and the ranges of values and determines whether appropriate skip patterns were followed. The Coordinating Center uploads the data onto a MESA intranet site for use by all study centers. Thus, all sites have access to their own data for read-only (query) purposes. The Coordinating Center creates reports summarizing the status of data collection. After data collection is complete, including that for designated interim periods, the data are cleaned and distributed to investigators.

## DISCUSSION

MESA will provide important new information about the pathophysiology of subclinical disease development and progression and its role in determining clinical CVD. Several major dimensions of subclinical CVD, including cardiac structure and function and conditions of the aorta, coronary arteries, peripheral arteries, and carotid arteries, and generalized measures of vascular function and compliance will be explored comprehensively and contemporaneously. Assessment of biochemical and genetic factors in major pathophysiologic domains will complement these measures. MESA has the potential to identify new risk factors for CVD and thus increase the ability to predict CVD and, ultimately, to allow the design of new prevention strategies. The ethnic diversity of the cohort, albeit limited to a small number of groups and some relatively small subgroups, is a unique feature and major strength of the study, permitting comparisons that may provide unique insights about interactions between ethnicity, risk factors, and subclinical and clinical CVD. It is hoped that the study's results will be applicable to clinical practice through the identification of noninvasive subclinical disease measures that best predict risk and through the suggestion of new approaches to prevent progression of subclinical disease.

## ACKNOWLEDGMENTS

This research is supported by contracts N01-HC-95159 through N01-HC-95169 with the National Heart, Lung, and Blood Institute.

Study centers and investigators in the Multi-Ethnic Study of Atherosclerosis: *Field Centers—Forsyth County, North Carolina*: Wake Forest University School of Medicine—Gregory Burke (Principal Investigator), Ronny Bell, J. Jeffrey Carr, J. Robin Crouse, Ralph B. D'Agostino, Jr., David Goff, David Herrington, Gregory Hundley, Sharon Jackson, and Cathy Nunn; *St. Paul, Minnesota*: University of Minnesota—Aaron Folsom (Principal Investigator), Donna Arnett, Alan Bank, Christine Dwight, David R. Jacobs, Jr., Michael Jerosch-Herold, Pamela Schreiner, Eyal Shahar, Charles Dietz, Lori Boland, Laura Kemmis, Mary Olson, Ana Diaz, Roberto Galaviz, Jackie Muñoz, Gail Murton, Michelle Neely, Mary Rosas, Esther Ruiz, Modesto Vasquez, and Pilar Velasquez; *Chicago, Illinois*: Northwestern University—Kiang Liu (Principal Investigator), Martha Daviglus, Paul Finn, David Green, Philip Greenland, David McPherson, William Pearce, and Michelle Woods; University of Illinois—George Kondos; Loyola University—Richard Cooper; *New York, New York*: Columbia University—Steven Shea (Principal Investigator), Olga Castro, Ana Diez Roux, Marco DiTullio, Geoffrey Gibson, Shunichi Homma, Carmen Isasi, Ralph Sacco, Rola Saouaf, and Alan Tall; St. Francis Hospital—Yadon Arad and Alan Guerci; *Baltimore, Maryland*: Johns Hopkins University—Moyses Szklo (Principal Investigator), T. J. Blake, Roger Blumenthal, Carol Christman, Joel Hill, João Lima, Javier Nieto, Pamela Ouyang, and Wendy Post; *Los Angeles, California*: University of California, Los Angeles—Mohammed Saad (Principal Investigator), Linda Demer, Alan Fogelman, Jonathan Goldin, Antoinette Gomes, Edward Grant, Rebecca Hua, Willa Hsueh, Sujata Jinagouda, Michael McNitt-Gray, Ying Mou, Shantanu Sinha, and Nancy Zambrana; *Central Laboratory*—University of Vermont: Russell P. Tracy (Principal Investigator), Elaine Cornell, Mary Cushman, and Nancy Jenny; University of Minnesota: Naomi Hanson and Michael Tsai; *Electrocardiogram Reading Center*—Ronald Prineas (Principal Investigator) and Farida Rautaharju; *Ultrasound Reading Center*—New England Medical Center: Daniel O'Leary (Principal Investigator), Laurie Funk, and Joseph Polak; *MRI Reading Center*—Department of Radiology, Johns Hopkins University: David Bluemke (Principal Investigator), João Lima, and Linda Wilkins; *CT Reading Center*—Harbor-UCLA Research and Education Institute: Robert Detrano (Principal Investigator), Matthew Budoff, Chris Dailing, Hans Fischer, Jeffrey Phillips, Susan Rice, and Nan Zhuang; University of California at Irvine: Nathan Wong; University of California at San Diego: Michael Criqui; *Coordinating Center*—University of Washington: Richard Kronmal (Principal Investigator), Melissa Anderson, Norma Dermond, Annette Fitzpatrick, Susan Heckbert, Bonnie Lind, Will Longstreth, Jennifer Clark Nelson, Bruce Psaty, David Siscovick, and Patricia Wahl; *Project Office*—National Heart, Lung, and Blood Institute: Diane Bild (Project Officer), Andrew Arai, Robin Boineau, Teri Manolio, Jean Olson, and A. Richey Sharrett.

## REFERENCES

1. Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Heart Study. *Ann Intern Med* 1989;110:101–7.
2. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med* 1999;340:14–22.
3. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. *Arterioscler Thromb* 1991;11:1245–9.
4. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. *Am J Epidemiol* 1997;146:483–94.
5. Blankenhorn DH. Coronary calcification, a review. *Am J Med Sci* 1961;242:1–9.
6. Loria CM, Detrano R, Liu K, et al. Sex and race differences in prevalence and predictors of early coronary calcification: The CARDIA Study. (Abstract). *Circulation* 2002;105:24.
7. Newman AB, Naydeck BL, Whittle J, et al. Racial differences in coronary calcification in older adults. *Arterioscler Thromb Vasc Biol* 2002;22:424–30.
8. Mautner GC, Mautner SL, Froehlich J, et al. Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation. *Radiology* 1994;192:619–23.
9. Rumberger JA, Simons DB, Fitzpatrick LA, et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. *Circulation* 1995;92:2157–162.
10. Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. *J Am Coll Cardiol* 1996;27:285–90.
11. Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. *Circulation* 2000;101:850–5.
12. van der Wall EE, Vliegen HW, de Roos A, et al. Magnetic resonance imaging in coronary artery disease. *Circulation* 1995;92:2723–39.
13. Lorenz CH, Walker ES, Morgan VL, et al. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. *J Cardiovasc Magn Reson* 1999;1:7–21.
14. Pattynama PM, Lamb HJ, van der Velde EA, et al. Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. *Radiology* 1993;187:261–8.
15. Altbach MI, Mattingly MA, Broom MF, et al. Magnetic resonance imaging of lipid deposits in human atheroma via a stimulated-echo diffusion-weighted technique. *Magn Reson Med* 1991;20:319–26.
16. Yuan C, Beach KW, Smith LH Jr, et al. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. *Circulation* 1998;98:2666–71.
17. Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor? *Am J Epidemiol* 1994;140:669–82.
18. Salomaa V, Riley W, Kark JD, et al. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: The ARIC Study. *Circulation* 1995;91:1432–43.
19. Chowienczyk PJ, Watts GF, Cockcroft JR, et al. Sex differences in endothelial function in normal and hypercholesterolaemic subjects. *Lancet* 1994;344:305–6.
20. Cockcroft JR, Chowienczyk PJ, Benjamin N, et al. Preserved endothelium-dependent vasodilatation in patients with essential



- hypertension. *N Engl J Med* 1994;330:1036–140.
21. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med* 1992;326:381–6.
  22. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. *Circulation* 1993;88:837–45.
  23. McVeigh GE, Bratteli CW, Morgan DJ, et al. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. *Hypertension* 1999;33:1392–8.
  24. Cohn JN, Finkelstein SM, McVeigh GE, et al. Noninvasive pulse wave analysis for the early detection of vascular disease. *Hypertension* 1995;26:503–8.
  25. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: The Bogalusa Heart Study. *N Engl J Med* 1998;338:1650–6.
  26. Davis PH, Dawson JD, Mahoney LT, et al. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults: The Muscatine Study. *Circulation* 1999;100:838–42.
  27. Wilson PW, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. *N Engl J Med* 1997;337:516–22.
  28. Davidson MH. Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. *Am J Cardiol* 2001;87:1A–7A.
  29. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999;340:115–26.
  30. Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentration and smoking: a preliminary report from the Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *JAMA* 1990;264:3018–24.
  31. Tintut Y, Patel J, Territo M, et al. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. *Circulation* 2002;105:650–5.
  32. Watson KE, Demer LL. The atherosclerosis-calcification link? *Curr Opin Lipidol* 1996;7:101–4.
  33. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. *Circulation* 2000;100:e20–8.
  34. Pahor M, Elam MB. Emerging noninvasive biochemical measures to predict cardiovascular risk. *Arch Intern Med* 1999;159:237–45.
  35. Folsom AR, Wu KK, Shahar E, et al. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Arterioscler Thromb* 1993;13:1829–36.
  36. Folsom AR, Wu K, Rosamond W, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 1997;96:1102–8.
  37. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. *Circulation* 1996;93:1809–17.
  38. Huber SA, Sakkinen P, David C, et al. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. *Circulation* 2001;103:2610–16.
  39. Tracy RP. Inflammation markers and coronary heart disease. *Curr Opin Lipidol* 1999;10:435–41.
  40. Ma J, Folsom A, Lewis L, et al. Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: The Atherosclerosis Risk in Communities (ARIC) Study. *Am J Clin Nutr* 1997;65:551–9.
  41. Shahar E, Folsom AR, Wu KK, et al. Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile: The Atherosclerosis Risk in Communities (ARIC) Study. *Arterioscler Thromb* 1993;13:1205–12.
  42. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. *Lancet* 1999;353:1729–34.
  43. Ellsworth DL, Manolio TA. The emerging importance of genetics in epidemiologic research. I. Basic concepts in human genetics and laboratory technology. *Ann Epidemiol* 1999;9:1–16.
  44. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men. *Ann Intern Med* 1997;127:111–18.
  45. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. *N Engl J Med* 1998;339:861–7.
  46. Sorlie PD, Backlund E, Johnson NJ, et al. Mortality by Hispanic status in the United States. *JAMA* 1993;270:2464–8.
  47. Nichaman M, Wear M, Goff D, et al. Hospitalization rates for myocardial infarction among Mexican-Americans and non-Hispanic Whites. *Ann Epidemiol* 1993;3:42–8.
  48. Goff D, Nichaman M, Chan W, et al. Greater incidence of hospitalized myocardial infarction among Mexican Americans than non-Hispanic whites: the Corpus Christi Heart Project, 1988–1992. *Circulation* 1997;95:1433–40.
  49. Frerichs RR, Chapman JM, Maes EF. Mortality due to all causes and to cardiovascular diseases among seven race-ethnic populations in Los Angeles County, 1980. *Int J Epidemiol* 1984;13:291–8.
  50. Menotti A, Keys A, Kromhout D, et al. Inter-cohort differences in coronary heart disease mortality in the 25-year follow-up of the Seven Countries Study. *Eur J Epidemiol* 1993;9:527–36.
  51. National Institutes of Health, Office of Extramural Research. Inclusion of women and minorities as participants in research involving human subjects—policy implementation page. Bethesda, MD: National Institutes of Health, 2001. ([http://grants.nih.gov/grants/funding/women\\_min/women\\_min.htm](http://grants.nih.gov/grants/funding/women_min/women_min.htm)).
  52. Janowitz W, Agatston A, Kaplan G, et al. Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. *Am J Cardiol* 1993;72:247–54.
  53. Maher JE, Bielak LF, Raz JA, et al. Progression of coronary artery calcification: a pilot study. *Mayo Clin Proc* 1999;74:347–55.
  54. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. *N Engl J Med* 1998;339:1972–8.
  55. MacKay AP, Fingerhut LA, Duran CR. Adolescent health chartbook. Health, United States, 2000. Hyattsville, MD: National Center for Health Statistics, 2000. (DHHS publication no. 00-1232).
  56. Psaty BM, Lee M, Savage PJ, et al. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. *J Clin Epidemiol* 1992;45:683–92.
  57. Block G, Woods M, Potosky A, et al. Validation of a self-

- administered diet history questionnaire using multiple diet records. *J Clin Epidemiol* 1990;43:1327–35.
58. Mayer-Davis EJ, Vitolins MZ, Carmichael SL, et al. Validity and reproducibility of a food frequency interview in a multi-cultural epidemiologic study. *Ann Epidemiol* 1999;9:314–24.
  59. Spielberger CD. Preliminary manual for the State-Trait personality inventory. Palo Alto, CA: Consulting Psychologist Press, 1980.
  60. Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. *Appl Psychol Meas* 1977;1:385–401.
  61. ENRICH Investigators. Enhancing Recovery in Coronary Heart Disease Patients (ENRICH): study design and methods. *Am Heart J* 2000;139:1–9.
  62. Bromberger JT, Matthews KA. A longitudinal study of the effects of pessimism, trait anxiety, and life stress on depressive symptoms in middle-aged women. *Psychol Aging* 1996;11:207–13.
  63. Williams DR. Race and health: basic questions, emerging directions. *Ann Epidemiol* 1997;7:322–33.
  64. Krieger N, Sidney S. Racial discrimination and blood pressure: the CARDIA Study of young black and white adults. *Am J Public Health* 1996;86:1370–8.
  65. Sampson RJ, Raudenbush SW, Earls F. Neighborhoods and violent crime: a multilevel study of collective efficacy. *Science* 1997;277:918–24.
  66. Scheier MF, Carver CS. Optimism, coping, and health: assessment and implications of generalized outcome expectancies. *Health Psychol* 1985;4:219–47.
  67. Barefoot JC, Dodge KA, Peterson BL, et al. The Cook-Medley hostility scale: item content and ability to predict survival. *Psychosom Med* 1989;51:46–57.
  68. Levin JS, Taylor RJ, Chatters LM. Race and gender differences in religiosity among older adults: findings from four national surveys. *J Gerontol* 1994;49:S137–54.
  69. Karasek R, Brisson C, Kawakami N, et al. The Job Content Questionnaire (JCQ): an instrument for internationally comparative assessments of psychosocial job characteristics. *J Occup Health Psychol* 1998;3:322–55.
  70. Ware JJ, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220–33.
  71. Ramsey M 3rd. Blood pressure monitoring: automated oscillometric devices. *J Clin Monit* 1991;7:56–67.
  72. Breen JF, Sheedy PF, Schwartz RS, et al. Coronary artery calcification detected with ultrafast CT as an indication of coronary artery disease. *Radiology* 1992;185:435–9.
  73. Carr JJ, Crouse JR, Goff DC, et al. Evaluation of sub-second gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. *Am J Radiol* 2000;174:915–21.
  74. Baur LH, Schipperheyn JJ, van der Velde EA, et al. Reproducibility of left ventricular size, shape and mass with echocardiography, magnetic resonance imaging and radionuclide angiography in patients with anterior wall infarction: a plea for core laboratories. *Int J Card Imaging* 1996;12:233–40.
  75. Marcus JT, DeWall LK, Gotte MJ, et al. MRI-derived left ventricular function parameters and mass in healthy young adults: relation with gender and body size. *Int J Card Imaging* 1999;15:411–19.
  76. Hatsukami TS, Ross R, Rolissar NL, et al. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. *Circulation* 2000;102:959–64.
  77. O'Leary DH, Polak JF, Kronmal RA, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly: The Cardiovascular Health Study. *Stroke* 1991;22:1155–63.
  78. Lage SG, Monachini MC, Medeiros CJ, et al. Carotid arterial compliance in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. *Am J Cardiol* 1994;74:691–5.
  79. Lage SG, Polak JF, O'Leary D, et al. Relationship of arterial compliance to baroreflex function in hypertensive patients. *Am J Physiol* 1993;265:H232–7.
  80. Celermaier DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 1992;340:1111–15.
  81. McVeigh GE, Bratteli CW, Morgan DJ, et al. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. *Hypertension* 1999;33:1392–8.
  82. McDermott MM, Criqui MH, Liu K, et al. Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressure, and association with leg functioning in peripheral arterial disease. *J Vasc Surg* 2000;32:1164–71.
  83. Rautaharju PM, Park LP, Chaitman BR, et al. The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. *J Electrocardiol* 1998;31:157–87.
  84. Self SG, Mauritsen RH, Ohara J. Power calculations for likelihood ratio tests in generalized linear models. *Biometrics* 1992;48:31–9.

---

## APPENDIX

### Major Subclinical Cardiovascular Disease Variables on which Data are Available for Analysis, Multi-Ethnic Study of Atherosclerosis, 2000–2007

#### Cardiac computed tomography

Agatston score, volume, volumetric score, and mass for the four major coronary arteries and for the sum of all arteries

#### Carotid ultrasound

Intimal-medial thickness measurements of left and right common and internal carotid arteries

Lumen measurements for both left and right carotid arteries

Normal lumen diameter for common and internal carotid artery

Minimum residual lumen diameter for common and internal carotid artery

Lesion measurements for both left and right carotid arteries

Maximum lesion width

Density of plaque

Homogeneity of plaque

Plaque surface

Doppler velocity at point of maximum disease

Densibility of the common carotid artery

#### Endothelial function

Percent reactivity

#### Cardiac magnetic resonance imaging

Left ventricular mass

End diastolic volume

End systolic volume

Ejection fraction

Stoke volume

Cardiac output  
End diastolic wall thickness  
End systolic wall thickness  
Thoracic aorta distensibility  
Thoracic aorta cross-sectional area  
Carotid magnetic resonance imaging  
Plaque characterization

Ankle-brachial index  
Electrocardiography and rhythm strip  
Major and minor electrocardiogram abnormalities  
R-R variability  
Arterial wave form  
Large artery elasticity index  
Small artery elasticity index